Clinical progress of advanced non-small cell lung cancer with epidermal growth factor receptor mutation in China

VernacularTitle:我国表皮生长因子受体突变晚期非小细胞肺癌的临床研究进展
Author: Xia SONG ¹ ; Hao TIAN ; Haibo ZHU ; Ruifen TIAN
Author Information

1. 山西省肿瘤医院呼吸二病区
Keywords: Carcinoma; non-small cell lung; Receptor; epidermal growth factor; Tyrosine kinase inhibitor
From: Cancer Research and Clinic 2019;31(8):551-553
CountryChina
Language:Chinese
Abstract: Lung cancer is the most common malignant tumor worldwide. There are more than 700000 new cases diagnosed as lung cancer each year in China, of which 80％-85％ are non-small cell lung cancer (NSCLC). The mutation proportion of epidermal growth factor receptor (EGFR) may reach up to 40％-55％. EGFR-tyrosine kinase inhibitor (EGFR-TKI) has become the standard first-line treatment method for advanced NSCLC patients with EGFR mutation. Chinese oncologists have done a large number of clinical studies, providing an important evidence-based medicine proof for treatment of advanced NSCLC with EGFR mutation.